Impact of 68Ga-FAPI PET/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas
Pancreatic ductal carcinoma (PDAC) is a highly lethal cancer, and early detection and accurate staging are critical to prolonging survival. PDAC typically has a prominent stroma including cancer-associated fibroblasts that express fibroblast activation protein (FAP). FAP is a new target molecule for...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 1, 2021
|
| In: |
Journal of nuclear medicine
Year: 2021, Volume: 62, Issue: 6, Pages: 779-786 |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.120.253062 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.2967/jnumed.120.253062 Verlag, lizenzpflichtig, Volltext: https://jnm.snmjournals.org/content/62/6/779 |
| Author Notes: | Manuel Röhrich, Patrick Naumann, Frederik L. Giesel, Peter L. Choyke, Fabian Staudinger, Annika Wefers, Dawn P. Liew, Clemens Kratochwil, Hendrik Rathke, Jakob Liermann, Klaus Herfarth, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Matthias Lang, Stefan A. Koerber |
| Summary: | Pancreatic ductal carcinoma (PDAC) is a highly lethal cancer, and early detection and accurate staging are critical to prolonging survival. PDAC typically has a prominent stroma including cancer-associated fibroblasts that express fibroblast activation protein (FAP). FAP is a new target molecule for PET imaging of various tumors. In this retrospective study, we describe the clinical impact of PET/CT imaging using 68Ga-labeled FAP-inhibitors (68Ga-FAPI PET/CT) in 19 patients with PDAC (7 primary, 12 progressive/recurrent). |
|---|---|
| Item Description: | Im Titel ist die Zahl 68 hochgestellt Gesehen am 13.09.2022 |
| Physical Description: | Online Resource |
| ISSN: | 2159-662X |
| DOI: | 10.2967/jnumed.120.253062 |